- Home
- CRSP vs CRNX Comparison
CRSP vs CRNX Comparison
Compare CRSP & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRSP | CRNX |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.5B |
| IPO Year | 2016 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CRSP | CRNX |
|---|---|---|
| Price | $60.11 | $41.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 9 |
| Target Price | $70.00 | ★ $75.78 |
| AVG Volume (30 Days) | ★ 1.5M | 883.8K |
| Earning Date | 05-15-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $289,590,000.00 | $1,039,000.00 |
| Revenue This Year | $1,603.19 | $520.98 |
| Revenue Next Year | $78.75 | $874.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 9169.85 | N/A |
| 52 Week Low | $30.06 | $24.10 |
| 52 Week High | $78.48 | $57.99 |
Technical Indicators
Market Signals| Indicator | CRSP | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 61.24 | 32.20 |
| Support Level | $58.40 | $39.35 |
| Resistance Level | $60.40 | $46.05 |
| Average True Range (ATR) | 3.03 | 2.22 |
| MACD | 1.16 | -0.21 |
| Stochastic Oscillator | 86.78 | 7.18 |
Price Performance
Historical ComparisonAbout CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.